ALKS
Price
$44.18
Change
+$0.70 (+1.61%)
Updated
Oct 22 closing price
Capitalization
7.41B
11 days until earnings call
Intraday BUY SELL Signals
NBIX
Price
$143.29
Change
+$1.98 (+1.40%)
Updated
Oct 22 closing price
Capitalization
14.57B
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALKS vs NBIX

ALKS vs NBIX Comparison Chart in %
View a ticker or compare two or three
VS
ALKS vs. NBIX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a StrongBuy and NBIX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALKS with price predictions
Oct 22, 2026

Momentum Indicator for ALKS turns positive, indicating new upward trend

ALKS saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned positive. In 74 of the 102 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALKS's RSI Oscillator exited the oversold zone, 15 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for ALKS just turned positive on October 05, 2026. Looking at past instances where ALKS's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.

Following a +7.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in 201 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

ALKS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ALKS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 50 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.098) is normal, around the industry mean (10.407). P/E Ratio (110.450) is within average values for comparable stocks, (-6.173). ALKS's Projected Growth (PEG Ratio) (21.570) is very high in comparison to the industry average of (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (4.638) is also within normal values, averaging (178.797).

A.I.Advisor
a Summary for NBIX with price predictions
Oct 22, 2026

Momentum Indicator for NBIX turns positive, indicating new upward trend

NBIX saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 64 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Indicator exited the oversold zone, 20 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on October 20, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in 36 of 53 cases over the following month. The odds of a continued upward trend are 68%.

Following a +4.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 222 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

The Aroon Indicator for NBIX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.943) is normal, around the industry mean (10.407). P/E Ratio (20.325) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (178.797).

The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
ALKS vs NBIX: Fundamental Ratings
ALKS
NBIX
OUTLOOK RATING
1..100
2522
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
5056
SMR RATING
1..100
8544
PRICE GROWTH RATING
1..100
4658
P/E GROWTH RATING
1..100
189
SEASONALITY SCORE
1..100
2350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (60) in the Biotechnology industry is somewhat better than the same rating for ALKS (100). This means that NBIX’s stock grew somewhat faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (50) in the Biotechnology industry is in the same range as NBIX (56). This means that ALKS’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for ALKS (85). This means that NBIX’s stock grew somewhat faster than ALKS’s over the last 12 months.

ALKS's Price Growth Rating (46) in the Biotechnology industry is in the same range as NBIX (58). This means that ALKS’s stock grew similarly to NBIX’s over the last 12 months.

ALKS's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for NBIX (89). This means that ALKS’s stock grew significantly faster than NBIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSNBIX
RSI
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
57%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
68%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
70%
Declines
ODDS (%)
Bearish Trend 10 days ago
65%
Bearish Trend 11 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 1 day ago
52%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ALKS: $44.18 vs. NBIX: $143.29)
Brand notoriety: ALKS and NBIX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 83% vs. NBIX: 106%
Market capitalization -- ALKS: $7.41B vs. NBIX: $14.57B
ALKS [@Pharmaceuticals: Generic] is valued at $7.41B. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $14.57B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green while NBIX’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than NBIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while NBIX’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 4 bearish.
  • NBIX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а +10.17% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was +4.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.00%. For the same industry, the average monthly price growth was -9.86%, and the average quarterly price growth was +9.31%.

Reported Earning Dates

ALKS is expected to report earnings on Nov 03, 2026.

NBIX is expected to report earnings on Nov 02, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.00% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
ALKS
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CLOC25.05N/A
+0.02%
AAM Crescent CLO ETF (CLOC)
SDCP25.08N/A
N/A
Virtus Newfleet Short Duration Core Plus Bond ETF (SDCP)
QINT68.77-1.01
-1.45%
American Century Quality Diversified International ETF (QINT)
PAVE52.07-1.07
-2.01%
Global X U.S. Infrastructure Development ETF (PAVE)
FBOT37.27-0.98
-2.56%
Fidelity Disruptive Automation ETF (FBOT)